Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex

Hybridoma Cell Line D8H21, as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.

Potential Commercial Applications: Competitive Advantages:
  • A research material that can be used in the development of assays, validation of products or in quality control.
  • Speed up product development with NIH developed material that has already been tested and validated.


Ronald Germain (NIAID)  ➽ more inventions...

Intellectual Property:
Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-039)

Zhong G, et al. PMID 9391117

Licensing Contact:
Daniel Lee, J.D.
Email: daniel.lee5@nih.gov
Phone: 301-761-6327

OTT Reference No: B-021-1999-0
Updated: Dec 4, 2017